Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant
Stopped Sponsor decision
Conditions
- Hematopoietic Cell Transplantation Recipient
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
Interventions
- OTHER: Laboratory Biomarker Analysis
- DRUG: Melphalan Hydrochloride
- DRUG: Melphalan Hydrochloride
- OTHER: Pharmacological Study
Sponsor
Ohio State University Comprehensive Cancer Center
Collaborators